The 5 constituents in the munKNEE Psychedelic Drug Stocks Index were up 2.3%, on average, last week and are now up 1.8% MTD. Below is how each constituent stock performed week ending January 12th and MTD, along with their market capitalizations and any recent news, commentary and/or analysis on each company:
- Atai Life Sciences (ATAI): up 19.5% last week; up 39.0% MTD
- GH Research (GHRS): up 12.3% last week; up 4.0% MTD
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Market Capitalization: $297M
- Latest News, Commentary and/or Analysis:
- Incannex Healthcare (IXHL): up 4.9% last week; down 7.3% YTD
- is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- Market Capitalization: $1.7B
- Latest News, Commentary and/or Analysis:
- Mind Medicine (MNMD): down 3.2% last week; up 8.2% MTD
- Compass Pathways (CMPS): down 5.6% last week; down 3.5% MTD
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Market Capitalization: $530M
- Latest News, Commentary and/or Analysis:
- Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
Summary
The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.
More By This Author:
5 Largest Canadian Cannabis Stocks Down 5%, On Average, This Week
Largest American Cannabis Stocks Up 16.5% MTD
Quantum Computing Hardware Developers Index Down Last Week
.webp)
Comments
Log in or sign up to join the conversation.